Small molecule inhibitor of type I transforming growth factor-β receptor kinase ameliorates the inhibitory milieu in injured brain and promotes regeneration of nigrostriatal dopaminergic axons

Journal of Neuroscience Research

Volumn 89, Issue 3, 2011, Pages 381-393

  Yoshioka, Nozomu ^a,b   Kimura Kuroda, Junko ^a   Saito, Taro ^b   Kawamura, Koki ^a   Hisanaga, Shin Ichi ^b   Kawano, Hitoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO METROPOLITAN UNIVERSITY   (Japan)

Author keywords

Axonal regeneration; Chondroitin sulfate proteoglycans; Fibrotic scar; Glial scar; Traumatic brain injury

Indexed keywords

COLLAGEN TYPE 4; PHOSPHOTRANSFERASE; PROTEOCHONDROITIN SULFATE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXTRACELLULAR MATRIX; MALE; MOUSE; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION;

ANIMALS; ANTIGENS; ANTIGENS, CD45; AXONS; BRAIN INJURIES; CICATRIX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICE; MICE, INBRED ICR; NERVE REGENERATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; PYRAZOLES; PYRROLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 78751698461     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22552     Document Type: Article

References (61)

1. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JJ, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. 1999. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1: 260-266.
2. Asher RA, Morgenstern DA, Fidler PS, Adcock KH, Oohira A, Braistead JE, Levine JM, Margolis RU, Rogers JH, Fawcett JW. 2000. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci 20: 2427-2438.
3. Baghdassarian D, Toru-Delbauffe D, Gavaret JM, Pierre M. 1993. Effects of transforming growth factor-β1 on the extracellular matrix and cytoskeleton of cultured astrocytes. Glia 7: 193-202.
4. Berry M, Maxwell WL, Logan A, Mathewson A, McConnell P, Ashhurst DE, Thomas GH. 1983. Deposition of scar tissue in the central nervous system. Acta Neurochir Suppl 32: 31-53.
5. Boche D, Cunningham C, Gauldie J, Perry VH. 2003. Transforming growth factor-β1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab 23: 1174-1182.
6. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. 2002. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416: 636-640.
7. Brazda N, Müller HW. 2009. Pharmacological modification of the extracellular matrix to promote regeneration of the injured brain and spinal cord. Prog Brain Res 175: 269-281.
8. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, Johnson MH, Sofroniew MV. 1999. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23: 297-308.
9. Cafferty WB, Yang SH, Duffy PJ, Li S, Strittmatter SM. 2007. Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J Neurosci 27: 2176-2185.
10. Correale J, Villa A. 2004. The neuroprotective role of inflammation in nervous system injuries. J Neurol 251: 1304-1316.
11. Davies JE, Tang X, Denning JW, Archibald SJ, Davies SJ. 2004. Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries. Eur J Neurosci 19: 1226-1242.
12. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MW. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24: 2143-2155.
13. Fawcett JW, Asher RA. 1999. The glial scar and central nervous system repair. Brain Res Bull 49: 377-391.
14. Gris P, Tighe A, Levin D, Sharma R, Brown A. 2007. Transcriptional regulation of scar gene expression in primary astrocytes. Glia 55: 1145-1155.
15. Hamada Y, Ikata T, Katoh S, Katoh K, Niwa M, Tsutsumishita Y, Fukuzawa K. 1996. Effets of exogenous transforming growth factor-β1 on spinal cord injury in rats. Neurosci Lett 203: 97-100.
16. Homma A, Li HP, Hayashi K, Kawano Y, Kawano H. 2006. Differential response of arcuate proopiomelanocortin- and neuropeptide Y-containing neurons to the lesion produced by gold thioglucose administration. J Comp Neurol 499: 120-131.
17. Kano MR, Bae Y, Iwata C, Moriyama Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. 2007. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci U S A 104: 3460-3465.
18. Kawano H, Ohyama K, Kawamura K, Nagatsu I. 1995. Migration of dopaminergic neurons in the embryonic mesencephalon of mice. Brain Res Dev Brain Res 86: 101-113.
19. Kawano H, Li HP, Sango K, Kawamura K, Raisman G. 2005. Inhibition of collagen synthesis overrides the age-related failure of regeneration of nigrostriatal dopaminergic axons. J Neurosci Res 80: 191-202.
20. Kimura-Kuroda J, Teng X, Komura Y, Yoshioka N, Sango K, Kawamura K, Raisman G, Kawano H. 2010. An in vitro model of the inhibition of axon growth in the lesion scar formed after central nervous system injury. Mol Cell Neurosci 43: 177-187.
21. King VR, Phillips JB, Brown RA, Priestley JV. 2004. The effects of treatment with antibodies to transforming growth factor β1 and β2 following spinal cord damage in the adult rat. Neuroscience 126: 173-183.
22. Klapka N, Hermanns S, Straten G, Masanneck C, Duis S, Hamers FP, Müller D, Zuschratter W, Müller HW. 2005. Suppression of fibrous scarring in spinal cord injury of rat promotes long-distance regeneration of corticospinal tract axons, rescue of primary motoneurons in somatosensory cortex and significant functional recovery. Eur J Neurosci 22: 3047-3058.
23. Kohda M, Kohmura E, Yamashita T. 2009. Inhibition of TGF-β1 promotes functional recovery after spinal cord injury. Neurosci Res 65: 393-401.
24. Komuta Y, Teng X, Yanagisawa H, Sango K, Kawamura K, Kawano H. 2010. Expression of transforming growth factor-β receptors in meningeal fibroblasts of the injured mouse brain. Cell Mol Neurobiol 30: 101-111.
25. Laabs T, Wang H, Katagiri Y, McCann T, Fawcett JW, Geller HM. 2007. Inhibiting glycosaminoglycan chain polymerization decreases the inhibitory activity of astrocyte-derived chondroitin sulfate proteoglycans. J Neurosci 27: 14494-14501.
26. Lagord C, Berry M, Logan A. 2002. Expression of TGFβ2 but not TGF-β1 correlates with the deposition of scar tissue in the lesioned spinal cord. Mol Cell Neurosci 20: 69-92.
27. Li HP, Homma A, Sango K, Kawamura K, Raisman G, Kawano H. 2007. Regeneration of nigrostriatal dipaminergic axons by degradation of chondroitin sulfate is accompanied by elimination of the fibrotic scar and glia limitans in the lesion site. J Neurosci Res 85: 536-547.
28. Li Y, Field PM, Raisman G. 1997. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 277: 2000-2002.
29. Liesi P, Kauppila T. 2002. Induction of type IV collagen and other basement-membrane-associated proteins after spinal cord injury of the adult rat may participate in formation of the glial scar. Exp Neurol 173: 31-45.
30. Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird A. 1992. Enhanced expression of transforming growth factor β1 in the rat brain after a localized cerebral injury. Brain Res 587: 216-225.
31. Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird A. 1994. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci 6: 355-363.
32. Logan A, Green J, Hunter A, Jackson R, Berry M. 1999a. Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2. Eur J Neurosci 11: 2367-2374.
33. Logan A, Baird A, Berry M. 1999b. Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159: 504-510.
34. Makwana M, Jones LL, Cuthill D, Heuer H, Bohatschek M, Hristova M, Friedrichsen S, Ormsby I, Bueringer D, Koppius A, Bauer K, Doetschman T, Raivich G. 2007. Endogenous transforming growth factor β1 suppresses inflammation and promotes survival in adult CNS. J Neurosci 27: 11201-11213.
35. McAuliffe JJ, Joseph B, Hughes E, Miles L, Vorhees CV. 2008. Metallothionein I, II deficient mice do not exhibit significantly worse long-term behavioral outcomes following neonatal hypoxia-ischemia: MT-I, II deficient mice have inherent behavioral impairments. Brain Res 1190: 175-185.
36. McTigue DM, Popovich PG, Morgan TE, Stokes BT. 2000. Localization of transforming growth factorβ-1 and receptor mRNA after experimental spinal cord injury. Exp Neurol 163: 220-230.
37. 2. Eur J Neurosci 14: 1667-1677.
38. Moon LD, Asher RA, Rhodes KE, Fawcett JW. 2001. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat Neurosci 4: 465-466.
39. Nakamura M, Houghtling RA, MacArthur L, Bayer BM, Bregman BS. 2003. Differences in cytokine gene expression profile between acute and secondary injury in adult rat spinal cord. Exp Neurol 184: 313-325.
40. Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, Yamane J, Yoshimura A, Iwamoto Y, Toyama Y, Okano H. 2006. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12: 829-834.
41. Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CE. 1993. Transforming growth factor β1 and fibronectin messenger RNA in rat brain: responses to injury and cell-type localization. Neuroscience 54: 893-907.
42. Rhodes KE, Fawcett JW. 2004. Chondroitin sulfate proteoglycans: preventing plasticity or protecting the CNS? J Anat 204: 33-48.
43. Rhodes KE, Raivish G, Fawcett JW. 2006. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neuroscience 140: 87-100.
44. Roberts AB, Russo A, Felici A, Flanders KC. 2003. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann N Y Acad Sci 995: 1-10.
45. Sandvig A, Berry M, Barrett LB, Butt A, Logan A. 2004. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. Glia 46: 225-251.
46. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM. 2003. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 46: 3953-3956.
47. Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, Akassoglou K. 2010. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 30: 5843-5854.
48. Schiwy N, Brazda N, Müller HW. 2009. Enhanced regenerative axon growth of multiple fibre populations in traumatic spinal cord injury following scar-suppressing treatment. Eur J Neurosci 30: 1544-1553.
49. Semple-Rowland SL, Mahatme A, Popovich PG, Green DA, Hassler GJrStokes BT, Streit WJ. 1995. Analysis of TGF-β1 gene expression in contused rat spinal cord using quantitative RT-PCR. J Neurotrauma 12: 1003-1014.
50. Shearer MC, Fawcett JW. 2001. The astrocyte/meningeal cell interface-a barrier to successful nerve regeneration? Cell Tissue Res 305: 267-273.
51. Shi Y, Massagué J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
52. Silver J, Miller JH. 2004. Regeneration beyond the glial scar. Nat Rev Neurosci 5: 146-156.
53. Smith GM, Strunz C. 2005. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52: 209-218.
54. Stichel CC, Hermanns S, Luhmann HJ, Lausberg F, Niermann H, D'Urso D, Servos G, Hartwig HG, Müller HW. 1999a. Inhibition of collagen IV deposition promotes regeneration of injured CNS axons. Eur J Neurosci 11: 632-646.
55. Stichel CC, Niermann H, D'Urso D, Lausberg F, Hermanns S, Müller HW. 1999b. Basal membrane-depleted scar in lesioned CNS: characteristics and relationships with regenerating axons. Neuroscience 93: 321-333.
56. Teng X, Nagata I, Li HP, Kimura-Kuroda J, Sango K, Kawamura K, Raisman G, Kawano H. 2008. Regeneration of nigrostriatal dopaminergic axons after transplantation of olfactory ensheathing cells and fibroblasts prevents fibrotic scar formation at the lesion site. J Neurosci Res 86: 3140-3150.
57. Uemura K, Yokota Y, Kozutsumi Y, Kawasaki T. 1996. A unique CD45 glycoform recognized by the serum mannan-binding protein in immature thymocytes. J Biol Chem 271: 4581-4584.
58. Wang Y, Moges H, Bharucha Y, Symes A. 2007. Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp Neurol 203: 168-184.
59. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. 2009. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174: 519-533.
60. Yiu G, He Z. 2006. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7: 617-627.
61. Yoshioka N, Hisanaga S, Kawano H. 2010. Suppression of the fibrotic scar formation promotes axonal regeneration without disturbing the blood-brain barrier repair and withdrawal of leukocytes after traumatic brain injury. J Comp Neurol 518: 3867-3881.